Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2003.09.081 on February 13 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v21,p2446)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Citron, M. L.
Right arrow Articles by Norton, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Citron, M. L.
Right arrow Articles by Norton, L.
Related Articles
Right arrowRelated Correspondence
Right arrowRelated Reply
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 8 (April), 2003: 1431-1439
© 2003 American Society for Clinical Oncology

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741

Marc L. Citron, Donald A. Berry, Constance Cirrincione, Clifford Hudis, Eric P. Winer, William J. Gradishar, Nancy E. Davidson, Silvana Martino, Robert Livingston, James N. Ingle, Edith A. Perez, John Carpenter, David Hurd, James F. Holland, Barbara L. Smith, Carolyn I. Sartor, Eleanor H. Leung, Jeffrey Abrams, Richard L. Schilsky, Hyman B. Muss, Larry Norton

From the ProHEALTH Care Associates, LLP, Lake Success; and Memorial Sloan-Kettering Cancer Center and Mt Sinai School of Medicine, New York, NY; University of Texas M.D. Anderson Cancer Center, Houston, TX; Cancer and Leukemia Group B Statistical Office and Data Operations, Durham; Comprehensive Cancer Center of Wake Forest University, Winston-Salem; and University of North Carolina School of Medicine, Chapel Hill, NC; Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Massachusetts General Hospital, Boston, MA; Northwestern University and Cancer and Leukemia Group B Central Office, Chicago, IL; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, and National Cancer Institute, Bethesda, MD; John Wayne Cancer Institute, Santa Monica, CA; University of Washington, Seattle, WA; Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL; University of Alabama at Birmingham, Birmingham, AL; and University of Vermont, Burlington, VT.

Address reprint requests to Marc L. Citron, MD, ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042; email: mcitron{at}prohealthcare.com.

Purpose: Using a 2 x 2 factorial design, we studied the adjuvant chemotherapy of women with axillary node–positive breast cancer to compare sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) with concurrent doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) for disease-free (DFS) and overall survival (OS); to determine whether the dose density of the agents improves DFS and OS; and to compare toxicities.

Patients and Methods: A total of 2,005 female patients were randomly assigned to receive one of the following regimens: (I) sequential A x 4 (doses) -> T x 4 -> C x 4 with doses every 3 weeks, (II) sequential A x 4 -> T x 4 -> C x 4 every 2 weeks with filgrastim, (III) concurrent AC x 4 -> T x 4 every 3 weeks, or (IV) concurrent AC x 4 -> T x 4 every 2 weeks with filgrastim.

Results: A protocol-specified analysis was performed at a median follow-up of 36 months: 315 patients had experienced relapse or died, compared with 515 expected treatment failures. Dose-dense treatment improved the primary end point, DFS (risk ratio [RR] = 0.74; P = .010), and OS (RR = 0.69; P = .013). Four-year DFS was 82% for the dose-dense regimens and 75% for the others. There was no difference in either DFS or OS between the concurrent and sequential schedules. There was no interaction between density and sequence. Severe neutropenia was less frequent in patients who received the dose-dense regimens.

Conclusion: Dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time. Sequential chemotherapy is as effective as concurrent chemotherapy.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Correspondence

  • Improved Outcome With Dose-Dense Chemotherapy
    Bruce Keith, Rob Hall, and Aaron Scholnik
    JCO 2004 22: 749 [Full Text]
  • Dose-Dense Chemotherapy As Adjuvant Treatment for Breast Cancer
    Carl D. Atkins
    JCO 2004 22: 749-780 [Full Text]
  • Dose Density by Any Other Name
    William Hryniuk, Joseph Ragaz, and William Peters
    JCO 2004 22: 750-751 [Full Text]

Related Reply

  • In Reply:
    Marc L. Citron, Donald A. Berry, Constance Cirrincione, Clifford Hudis, Larry Norton, Eric P. Winer, William J. Gradishar, Nancy E. Davidson, Silvana Martino, Robert Livingston, James N. Ingle, John Carpenter, David Hurd, James F. Holland, Barbara Smith, Carolyn I. Sartor, Eleanor H. Leung, Jeffrey Abrams, Richard L Schilsky, and Hyman B. Muss
    JCO 2004 22: 751-753 [Full Text]


This article has been cited by other articles:


Home page
 JCOHome page
L. Gianni, L. Norton, N. Wolmark, T. M. Suter, G. Bonadonna, and G. N. Hortobagyi
Role of Anthracyclines in the Treatment of Early Breast Cancer
J. Clin. Oncol., October 1, 2009; 27(28): 4798 - 4808.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Robson and S. Verma
Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?
Oncologist, October 1, 2009; 14(10): 950 - 958.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. I. Pritchard
Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?
Oncologist, October 1, 2009; 14(10): 959 - 962.
[Full Text] [PDF]

Home page
 JCOHome page
M. I. Milowsky, D. M. Nanus, F. C. Maluf, S. Mironov, W. Shi, A. Iasonos, J. Riches, A. Regazzi, and D. F. Bajorin
Final Results of Sequential Doxorubicin Plus Gemcitabine and Ifosfamide, Paclitaxel, and Cisplatin Chemotherapy in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium
J. Clin. Oncol., September 1, 2009; 27(25): 4062 - 4067.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Frasci, P. Comella, M. Rinaldo, G. Iodice, M. Di Bonito, M. D'Aiuto, A. Petrillo, S. Lastoria, C. Siani, G. Comella, et al.
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer
Ann. Onc., July 1, 2009; 20(7): 1185 - 1192.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Untch, V. Mobus, W. Kuhn, B. R. Muck, C. Thomssen, I. Bauerfeind, N. Harbeck, C. Werner, A. Lebeau, A. Schneeweiss, et al.
Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer
J. Clin. Oncol., June 20, 2009; 27(18): 2938 - 2945.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. C. Zellars, V. Stearns, D. Frassica, F. Asrari, T. Tsangaris, L. Myers, S. DiPasquale, J. R. Lange, L. K. Jacobs, L. A. Emens, et al.
Feasibility Trial of Partial Breast Irradiation With Concurrent Dose-Dense Doxorubicin and Cyclophosphamide in Early-Stage Breast Cancer
J. Clin. Oncol., June 10, 2009; 27(17): 2816 - 2822.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Hershman, J. M. Unger, W. E. Barlow, L. F. Hutchins, S. Martino, C. K. Osborne, R. B. Livingston, and K. S. Albain
Treatment Quality and Outcomes of African American Versus White Breast Cancer Patients: Retrospective Analysis of Southwest Oncology Studies S8814/S8897
J. Clin. Oncol., May 1, 2009; 27(13): 2157 - 2162.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Sparano, S. Moulder, A. Kazi, D. Coppola, A. Negassa, L. Vahdat, T. Li, C. Pellegrino, S. Fineberg, P. Munster, et al.
Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer
Clin. Cancer Res., April 15, 2009; 15(8): 2942 - 2948.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Jones, F. A. Holmes, J. O'Shaughnessy, J. L. Blum, S. J. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. L. Kirby, J. Sandbach, et al.
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
J. Clin. Oncol., March 10, 2009; 27(8): 1177 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Gianni and P. Valagussa
Anthracyclines and Early Breast Cancer: The End of an Era?
J. Clin. Oncol., March 10, 2009; 27(8): 1155 - 1157.
[Full Text] [PDF]

Home page
 Ann OncolHome page
R. Yerushalmi, M. R. Kramer, S. Rizel, A. Sulkes, K. Gelmon, T. Granot, V. Neiman, and S. M. Stemmer
Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study
Ann. Onc., March 1, 2009; 20(3): 437 - 440.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
P. G. Morris, H. L. McArthur, C. T. Dang, and C. A. Hudis
Selection of Appropriate Patients for Anthracycline Therapy
ASCO Educational Book, January 1, 2009; 2009(1): 11 - 18.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. I. Olopade, T. A. Grushko, R. Nanda, and D. Huo
Advances in Breast Cancer: Pathways to Personalized Medicine
Clin. Cancer Res., December 15, 2008; 14(24): 7988 - 7999.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. P. Schneider, E. P. Winer, W. D. Foulkes, J. Garber, C. M. Perou, A. Richardson, G. W. Sledge, and L. A. Carey
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Clin. Cancer Res., December 15, 2008; 14(24): 8010 - 8018.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. de la Cruz-Merino, E. Grande-Pulido, A. Albero-Tamarit, and M. E. Codes-Manuel de Villena
Cancer and Immune Response: Old and New Evidence for Future Challenges
Oncologist, December 1, 2008; 13(12): 1246 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Somlo, P. Chu, P. Frankel, W. Ye, S. Groshen, J. H. Doroshow, K. Danenberg, and P. Danenberg
Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome
Ann. Onc., November 1, 2008; 19(11): 1853 - 1859.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. S. Mehta, T. Schubbert, and K. Kong
Trastuzumab in inflammatory breast cancer
Ann. Onc., October 1, 2008; 19(10): 1815 - 1817.
[Full Text] [PDF]

Home page
 The OncologistHome page
G. Russo, R. Haddad, M. Posner, and M. Machtay
Radiation Treatment Breaks and Ulcerative Mucositis in Head and Neck Cancer
Oncologist, August 1, 2008; 13(8): 886 - 898.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Dang, L. Norton, and C. Hudis
Dose-Dense Chemotherapy With Trastuzumab Is an Appropriate Option
J. Clin. Oncol., July 20, 2008; 26(21): 3655 - 3656.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. R. Zander, C. Schmoor, N. Kroger, W. Kruger, V. Mobus, N. Frickhofen, B. Metzner, W. E. Berdel, M. Koenigsmann, E. Thiel, et al.
Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up
Ann. Onc., June 1, 2008; 19(6): 1082 - 1089.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Fountzilas, U. Dafni, H. Gogas, H. Linardou, H. P. Kalofonos, E. Briasoulis, D. Pectasides, E. Samantas, D. Bafaloukos, G. P. Stathopoulos, et al.
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
Ann. Onc., May 1, 2008; 19(5): 853 - 860.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Sparano, M. Wang, S. Martino, V. Jones, E. A. Perez, T. Saphner, A. C. Wolff, G. W. Sledge Jr., W. C. Wood, and N. E. Davidson
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
N. Engl. J. Med., April 17, 2008; 358(16): 1663 - 1671.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. A. Traina, M. Theodoulou, K. Feigin, S. Patil, K. L. Tan, C. Edwards, U. Dugan, L. Norton, and C. Hudis
Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer
J. Clin. Oncol., April 10, 2008; 26(11): 1797 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Gonzalez-Angulo and G. N. Hortobagyi
Optimal Schedule of Paclitaxel: Weekly Is Better
J. Clin. Oncol., April 1, 2008; 26(10): 1585 - 1587.
[Full Text] [PDF]

Home page
 The OncologistHome page
I. Vergote, F. Amant, K. Leunen, I. Cadron, T. Van Gorp, P. Neven, and P. Berteloot
Intraperitoneal Chemotherapy in Patients with Advanced Ovarian Cancer: The Con View
Oncologist, April 1, 2008; 13(4): 410 - 414.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. L. Mayer and H. J. Burstein
Weighing a Dose-Dense Option for Adjuvant Chemotherapy and Trastuzumab in Early-Stage Breast Cancer
J. Clin. Oncol., March 10, 2008; 26(8): 1198 - 1200.
[Full Text] [PDF]

Home page
 JCOHome page
C. Dang, M. Fornier, S. Sugarman, T. Troso-Sandoval, D. Lake, G. D'Andrea, A. Seidman, N. Sklarin, M. Dickler, V. Currie, et al.
The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer
J. Clin. Oncol., March 10, 2008; 26(8): 1216 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S.-C. Chen, H.-K. Chang, Y.-C. Lin, S. Hsueh, Y.-C. Cheung, W.-M. Leung, C.-S. Tsai, Y.-F. Lo, H.-P. Tsai, S.-C. Shen, et al.
High Pathologic Complete Response in HER 2-positive Locally Advanced Breast Cancer after Primary Systemic Chemotherapy with Weekly Docetaxel and Epirubicin
Jpn. J. Clin. Oncol., February 12, 2008; (2008) hym172v1.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
L.-P. P. Tran and J. L. Grabinski
Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux
Journal of Pharmacy Practice, February 1, 2008; 21(1): 46 - 56.
[Abstract] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
P. Francis, J. Crown, A. Di Leo, M. Buyse, A. Balil, M. Andersson, B. Nordenskjold, I. Lang, R. Jakesz, D. Vorobiof, et al.
Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial
J Natl Cancer Inst, January 16, 2008; 100(2): 121 - 133.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. H. Moskowitz, P. A. Hamlin, J. Gabrilove, J. R. Bertino, C. S. Portlock, D. J. Straus, A. N. Gencarelli, S. D. Nimer, and A. D. Zelenetz
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
Ann. Onc., November 1, 2007; 18(11): 1842 - 1850.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. F. Hayes, A. D. Thor, L. G. Dressler, D. Weaver, S. Edgerton, D. Cowan, G. Broadwater, L. J. Goldstein, S. Martino, J. N. Ingle, et al.
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
N. Engl. J. Med., October 11, 2007; 357(15): 1496 - 1506.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Moore
Breast-Cancer Therapy -- Looking Back to the Future
N. Engl. J. Med., October 11, 2007; 357(15): 1547 - 1549.
[Full Text] [PDF]

Home page
 JCOHome page
H. B. Muss, D. A. Berry, C. Cirrincione, D. R. Budman, I. C. Henderson, M. L. Citron, L. Norton, E. P. Winer, and C. A. Hudis
Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience
J. Clin. Oncol., August 20, 2007; 25(24): 3699 - 3704.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Denduluri, J. A. Low, J. J. Lee, A. W. Berman, J. M. Walshe, U. Vatas, C. K. Chow, S. M. Steinberg, S. X. Yang, and S. M. Swain
Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes
J. Clin. Oncol., August 10, 2007; 25(23): 3421 - 3427.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. M. Kuderer, D. C. Dale, J. Crawford, and G. H. Lyman
Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review
J. Clin. Oncol., July 20, 2007; 25(21): 3158 - 3167.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Layman, D. G. Thomas, K. A. Griffith, J. B. Smerage, M. A. Helvie, M. A. Roubidoux, K. M. Diehl, L. A. Newman, M. S. Sabel, J. A. Hayman, et al.
Neoadjuvant Docetaxel and Capecitabine and the Use of Thymidine Phosphorylase as a Predictive Biomarker in Breast Cancer
Clin. Cancer Res., July 15, 2007; 13(14): 4092 - 4097.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. Hershman, A. I. Neugut, and V. Grann
Response: Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
J Natl Cancer Inst, July 4, 2007; 99(13): 1051 - 1052.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Clavarezza, L. Del Mastro, P. Pronzato, P. Bruzzi, and M. Venturini
Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
J Natl Cancer Inst, July 4, 2007; 99(13): 1050 - 1051.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C Natoli, E Cianchetti, N Tinari, D Angelucci, A Grassadonia, M Zilli, C Ficorella, E Ricevuto, S Grossi, M De Tursi, et al.
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer
Ann. Onc., June 1, 2007; 18(6): 1015 - 1020.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Bouchardy, E. Rapiti, S. Blagojevic, A.-T. Vlastos, and G. Vlastos
Older Female Cancer Patients: Importance, Causes, and Consequences of Undertreatment
J. Clin. Oncol., May 10, 2007; 25(14): 1858 - 1869.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. C.F. Moore, S. J. Green, J. R. Gralow, S. I. Bearman, D. Lew, W. E. Barlow, C. Hudis, A. C. Wolff, J. N. Ingle, H. K. Chew, et al.
Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623
J. Clin. Oncol., May 1, 2007; 25(13): 1677 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. U. Buzdar
Adjuvant Chemotherapy for High-Risk Operable Breast Cancer
J. Clin. Oncol., May 1, 2007; 25(13): 1642 - 1644.
[Full Text] [PDF]

Home page
 BloodHome page
A. C. Hirbe, O. Uluckan, E. A. Morgan, M. C. Eagleton, J. L. Prior, D. Piwnica-Worms, K. Trinkaus, A. Apicelli, and K. Weilbaecher
Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner
Blood, April 15, 2007; 109(8): 3424 - 3431.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N Wilking, E Lidbrink, T Wiklund, B Erikstein, H Lindman, P Malmstrom, P Kellokumpu-Lehtinen, N-O Bengtsson, G Soderlund, G Anker, et al.
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Ann. Onc., April 1, 2007; 18(4): 694 - 700.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. Daubine, C. Le Gall, J. Gasser, J. Green, and P. Clezardin
Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone Metastasis
J Natl Cancer Inst, February 21, 2007; 99(4): 322 - 330.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. M. Linden, C. M. Haskell, S. J. Green, C. K. Osborne, G. W. Sledge Jr, C. L. Shapiro, J. N. Ingle, D. Lew, L. F. Hutchins, R. B. Livingston, et al.
Sequenced Compared With Simultaneous Anthracycline and Cyclophosphamide in High-Risk Stage I and II Breast Cancer: Final Analysis From INT-0137 (S9313)
J. Clin. Oncol., February 20, 2007; 25(6): 656 - 661.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
I. P. Touw and M. Bontenbal
Granulocyte Colony-Stimulating Factor: Key (F)actor or Innocent Bystander in the Development of Secondary Myeloid Malignancy?
J Natl Cancer Inst, February 7, 2007; 99(3): 183 - 186.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. Hershman, A. I. Neugut, J. S. Jacobson, J. Wang, W.-Y. Tsai, R. McBride, C. L. Bennett, and V. R. Grann
Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy
J Natl Cancer Inst, February 7, 2007; 99(3): 196 - 205.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
I. J. Lewis, M. A. Nooij, J. Whelan, M. R. Sydes, R. Grimer, P. C. W. Hogendoorn, M. A. Memon, S. Weeden, B. M. Uscinska, M. van Glabbeke, et al.
Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma Intergroup
J Natl Cancer Inst, January 17, 2007; 99(2): 112 - 128.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
H. Oettle, S. Post, P. Neuhaus, K. Gellert, J. Langrehr, K. Ridwelski, H. Schramm, J. Fahlke, C. Zuelke, C. Burkart, et al.
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial
JAMA, January 17, 2007; 297(3): 267 - 277.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. A. Kamat, T. J. Kim, C. N. Landen Jr., C. Lu, L. Y. Han, Y. G. Lin, W. M. Merritt, P. H. Thaker, D. M. Gershenson, F. Z. Bischoff, et al.
Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer
Cancer Res., January 1, 2007; 67(1): 281 - 288.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Piedbois, D Serin, F Priou, P Laplaige, S Greget, E Angellier, E Teissier, J-F Berdah, M Fabbro, B Valenza, et al.
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study
Ann. Onc., January 1, 2007; 18(1): 52 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. N. Fornier, A. D. Seidman, D. Lake, G. D'Andrea, J. Bromberg, M. Robson, C. Van Poznak, K. S. Panageas, M. Atienza, L. Norton, et al.
Increased Dose Density Is Feasible: A Pilot Study of Adjuvant Epirubicin and Cyclophosphamide followed by Paclitaxel, at 10- or 11-Day Intervals with Filgrastim Support in Women with Breast Cancer
Clin. Cancer Res., January 1, 2007; 13(1): 223 - 227.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Tolaney, A. H. Partridge, R. G. Sheib, H. J. Burstein, and E. P. Winer
Pneumocystis Carinii Pneumonia During Dose-Dense Chemotherapy for Breast Cancer
J. Clin. Oncol., November 20, 2006; 24(33): 5330 - 5331.
[Full Text] [PDF]

Home page
 NEJMHome page
M. N. Levine and T. Whelan
Adjuvant Chemotherapy for Breast Cancer -- 30 Years Later
N. Engl. J. Med., November 2, 2006; 355(18): 1920 - 1922.
[Full Text] [PDF]

Home page
 JCOHome page
M. Gore, A. du Bois, and I. Vergote
Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental
J. Clin. Oncol., October 1, 2006; 24(28): 4528 - 4530.
[Full Text] [PDF]

Home page
 Ann OncolHome page
E Bria, M Di Maio, C Nistico, F Cuppone, E Terzoli, F Cognetti, and D Giannarelli
Factorial design for randomized clinical trials
Ann. Onc., October 1, 2006; 17(10): 1607 - 1608.
[Full Text] [PDF]

Home page
 NEJMHome page
G. Ferretti, P. Papaldo, F. Cognetti, D. C. Dale, P. S. Rosenberg, B. P. Alter, and K. Kaushansky
Lineage-specific hematopoietic growth factors.
N. Engl. J. Med., August 3, 2006; 355(5): 526 - 527.
[Full Text] [PDF]

Home page
 JCOHome page
T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al.
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Papaldo, G. Ferretti, S. Di Cosimo, D. Giannarelli, P. Marolla, M. Lopez, E. Cortesi, M. Antimi, E. Terzoli, P. Carlini, et al.
Does Granulocyte Colony-Stimulating Factor Worsen Anemia in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide?
J. Clin. Oncol., July 1, 2006; 24(19): 3048 - 3055.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sparano, S. Moulder, A. Kazi, L. Vahdat, T. Li, C. Pellegrino, P. Munster, M. Malafa, D. Lee, S. Hoschander, et al.
Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide
J. Clin. Oncol., July 1, 2006; 24(19): 3013 - 3018.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Dang and C. Hudis
Can Granulocyte-Colony Stimulating Factor Worsen Anemia?
J. Clin. Oncol., July 1, 2006; 24(19): 2985 - 2986.
[Full Text] [PDF]

Home page
 JCOHome page
E. B. Elkin, A. Hurria, N. Mitra, D. Schrag, and K. S. Panageas
Adjuvant Chemotherapy and Survival in Older Women With Hormone Receptor-Negative Breast Cancer: Assessing Outcome in a Population-Based, Observational Cohort
J. Clin. Oncol., June 20, 2006; 24(18): 2757 - 2764.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. H. Malogolowkin, H. Katzenstein, M. D. Krailo, Z. Chen, L. Bowman, M. Reynolds, M. Finegold, B. Greffe, J. Rowland, K. Newman, et al.
Intensified Platinum Therapy Is an Ineffective Strategy for Improving Outcome in Pediatric Patients With Advanced Hepatoblastoma
J. Clin. Oncol., June 20, 2006; 24(18): 2879 - 2884.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum
Primary Systemic Therapy of Breast Cancer
Oncologist, June 1, 2006; 11(6): 574 - 589.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
R. S. Kerbel
Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
Science, May 26, 2006; 312(5777): 1171 - 1175.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. C. Wolff, R. J. Jones, N. E. Davidson, S. C. Jeter, and V. Stearns
Myeloid Toxicity in Breast Cancer Patients Receiving Adjuvant Chemotherapy With Pegfilgrastim Support
J. Clin. Oncol., May 20, 2006; 24(15): 2392 - 2394.
[Full Text] [PDF]

Home page
 JCOHome page
H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al.
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
J. Clin. Oncol., May 1, 2006; 24(13): 2019 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Monk, G. Phillips, R. Waite, J. Kuhn, L. J. Schaaf, G. A. Otterson, D. Guttridge, C. Rhoades, M. Shah, T. Criswell, et al.
Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients
J. Clin. Oncol., April 20, 2006; 24(12): 1852 - 1859.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. A. Berry, C. Cirrincione, I. C. Henderson, M. L. Citron, D. R. Budman, L. J. Goldstein, S. Martino, E. A. Perez, H. B. Muss, L. Norton, et al.
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
JAMA, April 12, 2006; 295(14): 1658 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Brade and I. F. Tannock
Scheduling of Radiation and Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Repopulation As a Cause of Treatment Failure?
J. Clin. Oncol., March 1, 2006; 24(7): 1020 - 1022.
[Full Text] [PDF]

Home page
 The OncologistHome page
S. Burdette-Radoux and H. B. Muss
Adjuvant chemotherapy in the elderly: whom to treat, what regimen?
Oncologist, March 1, 2006; 11(3): 234 - 242.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Oncologist, February 1, 2006; 11(2): 111 - 125.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
I. Smith and S. Chua
Medical treatment of early breast cancer. III: chemotherapy
BMJ, January 21, 2006; 332(7534): 161 - 162.
[Full Text] [PDF]

Home page
 JCOHome page
International Breast Cancer Study Group
Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95
J. Clin. Oncol., January 20, 2006; 24(3): 370 - 378.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
N. U. Lin, R. Gelman, and E. P. Winer
Dose Density in Breast Cancer: A Simple Message?
J Natl Cancer Inst, December 7, 2005; 97(23): 1712 - 1714.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Venturini, L. Del Mastro, E. Aitini, E. Baldini, C. Caroti, A. Contu, F. Testore, F. Brema, P. Pronzato, G. Cavazzini, et al.
Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial
J Natl Cancer Inst, December 7, 2005; 97(23): 1724 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Med.Home page
T. J Smith and J. Khatcheressian
Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer
Evid. Based Med., December 1, 2005; 10(6): 169 - 169.
[Full Text] [PDF]

Home page
 JCOHome page
H. J. Burstein, L. M. Parker, A. Keshaviah, J. Doherty, A. H. Partridge, L. Schapira, P. D. Ryan, J. Younger, L. N. Harris, B. Moy, et al.
Efficacy of Pegfilgrastim and Darbepoetin Alfa As Hematopoietic Support for Dose-Dense Every-2-Week Adjuvant Breast Cancer Chemotherapy
J. Clin. Oncol., November 20, 2005; 23(33): 8340 - 8347.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. W. Nyman, K. J. Campbell, E. Hersh, K. Long, K. Richardson, V. Trieu, N. Desai, M. J. Hawkins, and D. D. Von Hoff
Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies
J. Clin. Oncol., November 1, 2005; 23(31): 7785 - 7793.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Fountzilas, D. Skarlos, U. Dafni, H. Gogas, E. Briasoulis, D. Pectasides, C. Papadimitriou, C. Markopoulos, A. Polychronis, H. P. Kalofonos, et al.
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
Ann. Onc., November 1, 2005; 16(11): 1762 - 1771.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Cianfrocca and W. J. Gradishar
Controversies in the Therapy of Early Stage Breast Cancer
Oncologist, November 1, 2005; 10(10): 766 - 779.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online